Hyperthermic isolated perfusion with low-dose TNFalpha and doxorubicin in patients with locally advanced soft tissue limb sarcomas.
J Chemother
; 16 Suppl 5: 58-61, 2004 Nov.
Article
em En
| MEDLINE
| ID: mdl-15675481
ABSTRACT
We report here the results of 27 patients who underwent hyperthermic isolated limb perfusion with low-dose TNFalpha (1 mg) and doxorubicin (8.5 mg/l of limb volume) for locally advanced soft tissue sarcomas. A tumor response was observed in 85% of cases. After a median follow-up of 30 months, limb salvage and local disease control were achieved in 82 and 85% of patients, respectively. Locoregional toxicity was low or mild in 14 patients, while 2 patients had severe limb toxicity. Systemic side effects were negligible. The perfusate/plasma area under the curve (AUC) ratio for TNFalpha was 56. HILP with low-dose TNFalpha and DXR proved to be an active neoadjuvant drug regimen against limb-threatening STS.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Sarcoma
/
Quimioterapia do Câncer por Perfusão Regional
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Doxorrubicina
/
Fator de Necrose Tumoral alfa
/
Hipertermia Induzida
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Chemother
Assunto da revista:
ANTINEOPLASICOS
/
TERAPIA POR MEDICAMENTOS
Ano de publicação:
2004
Tipo de documento:
Article
País de afiliação:
Itália